13D Filing: Ventech Capital II and Eyegate Pharmaceuticals Inc (EYEG)

Page 1 of 11

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
FCPR Ventech A 574,763 0 574,763 0 574,763 3.5%
FCPR Ventech B 608,873 0 608,873 0 608,873 3.7%
FCPR Ventech Coinvest 961 0 961 0 961 0.0%
FCPR Ventech Capital II 1,589,121 0 1,589,121 0 1,589,121 9.7%
Alain Caffi 2,773,718 0 2,773,718 0 2,773,718 16.8%
Jean Bourcereau 2,773,718 0 2,773,718 0 2,773,718 16.8%

Page 1 of 11 – SEC Filing



Washington, D.C. 20549



Under the Securities Exchange Act of

(Amendment No. 1)


EyeGate Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

30233M 107

(CUSIP Number)

Stephen Brook, Esq.
Burns & Levinson LLP

125 Summer Street

Boston, MA 02110

(617) 345-3000

(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)

June 14, 2017

(Date of Event which Requires Filing of
this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies
are to be sent.


*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)

Page 1 of 11